Tempest Therapeutics (NASDAQ:TPST) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Tempest Therapeutics (NASDAQ:TPST – Free Report) in a research note issued to investors on Thursday, Benzinga reports. HC Wainwright currently has a $47.00 price target on the stock. Separately, Piper Sandler reiterated an overweight rating and issued a $8.00 price objective on shares of Tempest Therapeutics […]
More Stories
DA Davidson Forecasts Strong Price Appreciation for Booking (NASDAQ:BKNG) Stock
Booking (NASDAQ:BKNG – Get Free Report) had its price objective hoisted by research analysts at DA Davidson from $4,100.00 to...
Smurfit Westrock Announces Third Quarter Financial Results and Hosts Conference Call
Smurfit Westrock plc, an Ireland-based company known for its expertise in paper and packaging solutions, recently released its financial results...
Dine Brands Global (NYSE:DIN) Receives “Hold” Rating from Benchmark
Benchmark reiterated their hold rating on shares of Dine Brands Global (NYSE:DIN – Free Report) in a research report report...
HC Wainwright Lowers Ekso Bionics (NASDAQ:EKSO) Price Target to $9.00
Ekso Bionics (NASDAQ:EKSO – Free Report) had its price objective trimmed by HC Wainwright from $10.00 to $9.00 in a...
TriCo Bancshares (NASDAQ:TCBK) Price Target Lowered to $50.00 at Stephens
TriCo Bancshares (NASDAQ:TCBK – Free Report) had its price objective reduced by Stephens from $52.00 to $50.00 in a research...
F5 (NASDAQ:FFIV) Given New $241.00 Price Target at The Goldman Sachs Group
F5 (NASDAQ:FFIV – Free Report) had its price target lifted by The Goldman Sachs Group from $212.00 to $241.00 in...